Full text is available at the source.
Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double‐blind, placebo‐controlled pilot study
Applying rotigotine skin patches in moderate to advanced restless legs syndrome: a double-blind, placebo-controlled pilot study
AI simplified
Abstract
A significant improvement of 15.7 points on the International Restless Legs Syndrome Scale was observed with the highest dose of rotigotine compared to placebo.
- Rotigotine was tested in patients with moderate to severe idiopathic restless legs syndrome, including daytime symptoms.
- Three fixed doses of rotigotine (1.125 mg, 2.25 mg, and 4.5 mg) were applied via patches in a double-blind trial.
- RLS severity improved with increasing doses of rotigotine, with the 4.5 mg dose showing significant improvement compared to placebo.
- Daytime symptoms also significantly improved with all doses of rotigotine according to the RLS-6 scale.
- Skin tolerability and systemic side effects were comparable between rotigotine and placebo.
AI simplified